Screener
Stoke Therapeutics, Inc. STOK Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | $6,229 | $158,569 |
| Operating expenses: | ||
| Research and development | 39,673 | 32,676 |
| Sales, general and administrative | 19,974 | 14,653 |
| Total operating expenses | 59,647 | 47,329 |
| (Loss) income from operations | (53,418) | 111,240 |
| Other income (expense): | ||
| Interest income (expense), net | 3,397 | 2,889 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s total revenue?
- Stoke Therapeutics, Inc. (STOK) reported total revenue of $6.23M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s total revenue changed year-over-year?
- Stoke Therapeutics, Inc.'s total revenue decreased by 96.1% year-over-year, from $158.57M to $6.23M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s total revenue?
- Over 3 years (2022 to 2025), Stoke Therapeutics, Inc.'s total revenue has grown at a 145.9% compound annual growth rate (CAGR), from $12.4M to $184.42M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Stoke Therapeutics, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude